Your browser doesn't support javascript.
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
Ricke, Darrell O.
  • Ricke DO; Biological and Chemical Technologies, Massachusetts Institute of Technology Lincoln Laboratory, Biotechnology and Human Systems, Lexington, MA, United States.
Front Immunol ; 12: 640093, 2021.
Article in English | MEDLINE | ID: covidwho-1133915
ABSTRACT
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease progression include lymphopenia, elevated proinflammatory cytokines and chemokines, accumulation of macrophages and neutrophils in lungs, immune dysregulation, cytokine storms, acute respiratory distress syndrome (ARDS), etc. Development of vaccines to severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome coronavirus (MERS-CoV), and other coronavirus has been difficult to create due to vaccine induced enhanced disease responses in animal models. Multiple betacoronaviruses including SARS-CoV-2 and SARS-CoV-1 expand cellular tropism by infecting some phagocytic cells (immature macrophages and dendritic cells) via antibody bound Fc receptor uptake of virus. Antibody-dependent enhancement (ADE) may be involved in the clinical observation of increased severity of symptoms associated with early high levels of SARS-CoV-2 antibodies in patients. Infants with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 may also have ADE caused by maternally acquired SARS-CoV-2 antibodies bound to mast cells. ADE risks associated with SARS-CoV-2 has implications for COVID-19 and MIS-C treatments, B-cell vaccines, SARS-CoV-2 antibody therapy, and convalescent plasma therapy for patients. SARS-CoV-2 antibodies bound to mast cells may be involved in MIS-C and multisystem inflammatory syndrome in adults (MIS-A) following initial COVID-19 infection. SARS-CoV-2 antibodies bound to Fc receptors on macrophages and mast cells may represent two different mechanisms for ADE in patients. These two different ADE risks have possible implications for SARS-CoV-2 B-cell vaccines for subsets of populations based on age, cross-reactive antibodies, variabilities in antibody levels over time, and pregnancy. These models place increased emphasis on the importance of developing safe SARS-CoV-2 T cell vaccines that are not dependent upon antibodies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Phagocytes / Systemic Inflammatory Response Syndrome / Antibody-Dependent Enhancement / Middle East Respiratory Syndrome Coronavirus / SARS-CoV-2 / COVID-19 / Mast Cells Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Child / Female / Humans / Infant, Newborn / Pregnancy Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.640093

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Phagocytes / Systemic Inflammatory Response Syndrome / Antibody-Dependent Enhancement / Middle East Respiratory Syndrome Coronavirus / SARS-CoV-2 / COVID-19 / Mast Cells Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Child / Female / Humans / Infant, Newborn / Pregnancy Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.640093